Josca Schoonejans

Dr. Josca Schoonejans

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
JSJosca Schoonejans
Josca Schoonejans
SOSusan Elizabeth Ozanne
Susan Elizabeth Ozanne
The obesity epidemic has led to more women entering pregnancy overweight or obese. In addition to adverse short‐term outcomes, maternal obesity and/or gestational diabetes predispose offspring to developing obesity, type 2 diabetes and cardiovascular disease in adulthood through developmental programming. Human epidemiological studies, although vital in identifying associations, are often unable to address causality and mechanistic studies can be limited by the lack of accessibility of key metabolic tissues. Furthermore, multi‐generational studies take many years to complete. Integration of findings from human studies with those from animal models has therefore been critical in moving forward this field that has been termed the ‘Developmental Origins of Health and Disease’. This review summarises the evidence from animal models and highlights how animal models provide valuable insight into the maternal factors responsible for developmental programming, potential critical developmental windows, sexual dimorphism, molecular mechanisms and age‐related offspring outcomes throughout life. Moreover, we describe how animal models are vital to explore clinically relevant interventions to prevent adverse offspring outcomes in obese or glucose intolerant pregnancy, such as antioxidant supplementation, exercise and maternal metformin treatment.

Verified
Journal Article
Open access
PDF file
JSJosca Schoonejans
Josca Schoonejans
HBHeather Blackmore
Heather Blackmore
TAThomas J. Ashmore
Thomas J. Ashmore
CACatherine E. Aiken
Catherine E. Aiken
DTDenise Twinn
Denise Twinn
Susan OzanneSusan Ozanne
Susan Ozanne
Background: Metformin is commonly used to treat gestational diabetes mellitus. This study investigated the effect of maternal metformin intervention during obese glucose-intolerant pregnancy on the gonadal white adipose tissue (WAT) of 8-week-old male and female mouse offspring. Methods: C57BL/6J female mice were provided with a control (Con) or obesogenic diet (Ob) to induce pre-conception obesity. Half the obese dams were treated orally with 300 mg/kg/d of metformin (Ob-Met) during pregnancy. Gonadal WAT depots from 8-week-old offspring were investigated for adipocyte size, macrophage infiltration and mRNA expression of pro-inflammatory genes using RT-PCR. Results: Gestational metformin attenuated the adiposity in obese dams and increased the gestation length without correcting the offspring in utero growth restriction and catch-up growth caused by maternal obesity. Despite similar body weight, the Ob and Ob-Met offspring of both sexes showed adipocyte hypertrophy in young adulthood. Male Ob-Met offspring had increased WAT depot weight (p < 0.05), exaggerated adipocyte hyperplasia (p < 0.05 vs. Con and Ob offspring), increased macrophage infiltration measured via histology (p < 0.05) and the mRNA expression of F4/80 (p < 0.05). These changes were not observed in female Ob-Met offspring. Conclusions: Maternal metformin intervention during obese pregnancy causes excessive adiposity, adipocyte hyperplasia and WAT inflammation in male offspring, highlighting sex-specific effects of prenatal metformin exposure on offspring WAT.

16 September 2022 in Diabetologia
Verified
Journal Article
Open access
PDF file
JSJosca Schoonejans
Josca Schoonejans
HBHeather Blackmore
Heather Blackmore
TAThomas J. Ashmore
Thomas J. Ashmore
Lucas PantaleaoLucas Pantaleao
Lucas Pantaleao
LPLuciana Pisani
Luciana Pisani
Susan OzanneSusan Ozanne
Susan Ozanne
Aims/hypothesis: Metformin is increasingly used to treat gestational diabetes (GDM) and pregnancies complicated by pregestational type 2 diabetes or polycystic ovary syndrome but data regarding long-term offspring outcome are lacking in both human studies and animal models. Using a mouse model, this study investigated the effects of maternal metformin intervention during obese glucose-intolerant pregnancy on adiposity, hepatic steatosis and markers of metabolic health of male and female offspring up to the age of 12 months. Methods: C57BL/6J female mice were weaned onto either a control diet (Con) or, to induce pre-conception obesity, an obesogenic diet (Ob). The respective diets were maintained throughout pregnancy and lactation. These obese dams were then randomised to the untreated group or to receive 300 mg/kg oral metformin hydrochloride treatment (Ob-Met) daily during pregnancy. In male and female offspring, body weights and body composition were measured from 1 month until 12 months of age, when serum and tissues were collected for investigation of adipocyte cellularity (histology), adipose tissue inflammation (histology and quantitative RT-PCR), and hepatic steatosis and fibrosis (histochemistry and modified Folch assay). Results: At 12 months of age, male Ob and Ob-Met offspring showed increased adiposity, adipocyte hypertrophy, elevated expression of proinflammatory genes, hyperleptinaemia and hepatic lipid accumulation compared with Con offspring. Male Ob-Met offspring failed to show hyperplasia between 8 weeks and 12 months, indicative of restricted adipose tissue expansion, resulting in increased immune cell infiltration and ectopic lipid deposition. Female Ob offspring were relatively protected from these phenotypes but Ob-Met female offspring showed increased adiposity, adipose tissue inflammation, hepatic lipid accumulation, hyperleptinaemia and hyperinsulinaemia compared with Con female offspring. Conclusions/interpretation: Maternal metformin treatment of obese dams increased offspring metabolic risk factors in a sex- and age-dependent manner. These observations highlight the importance of following up offspring of both sexes beyond early adulthood after interventions during pregnancy. Our findings illustrate the complexity of balancing short-term benefits to mother and child vs any potential long-term metabolic effects on the offspring when prescribing therapeutic agents that cross the placenta. Graphical

18 October 2021 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
LMLaís Vales Mennitti
Laís Vales Mennitti
ACAsha A. M. Carpenter
Asha A. M. Carpenter
ELElena Loche
Elena Loche
LPLucas C. Pantaleão
Lucas C. Pantaleão
DTDenise Twinn
Denise Twinn
Susan OzanneSusan Ozanne
Susan Ozanne
Objective: This study investigated the effect of maternal obesity on aged-male offspring liver phenotype and hepatic expression of a programmed miRNA. Methods: A mouse model (C57BL/6 J) of maternal diet-induced obesity was used to investigate fasting-serum metabolites, hepatic lipid content, steatosis, and relative mRNA levels (RT-PCR) and protein expression (Western blotting) of key components involved in hepatic and mitochondrial metabolism in 12-month-old offspring. We also measured hepatic lipid peroxidation, mitochondrial content, fibrosis stage, and apoptosis in the offspring. To investigate potential mechanisms leading to the observed phenotype, we also measured the expression of miR-582 (a miRNA previously implicated in liver cirrhosis) in 8-week-old and 12-month-old offspring. Results: Body weight and composition was similar between 8-week-old offspring, however, 12-month-old offspring from obese mothers had increased body weight and fat mass (19.5 ± 0.8 g versus 10.4 ± 0.9 g, p < 0.001), as well as elevated serum levels of LDL and leptin and hepatic lipid content (21.4 ± 2.1 g versus 12.9 ± 1.8 g, p < 0.01). This was accompanied by steatosis, increased Bax/Bcl-2 ratio, and overexpression of p-SAPK/JNK, Tgfβ1, Map3k14, and Col1a1 in the liver. Decreased levels of Bcl-2, p-AMPKα, total AMPKα and mitochondrial complexes were also observed. Maternal obesity was associated with increased hepatic miR-582-3p (p < 0.001) and miR-582-5p (p < 0.05). Age was also associated with an increase in both miR-582-3p and miR-582-5p, however, this was more pronounced in the offspring of obese dams, such that differences were greater in 12-month-old animals (−3p: 7.34 ± 1.35 versus 1.39 ± 0.50, p < 0.0001 and −5p: 4.66 ± 1.16 versus 1.63 ± 0.65, p < 0.05). Conclusion: Our findings demonstrate that maternal diet-induced obesity has detrimental effects on offspring body composition as well as hepatic phenotype that may be indicative of accelerated-ageing phenotype. These whole-body and cellular phenotypes were associated with age-dependent changes in expression of miRNA-582 that might contribute mechanistically to the development of metabolic disorders in the older progeny.

29 February 2024 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
JSJosca Schoonejans
Josca Schoonejans
HFHei Man Fan
Hei Man Fan
AMAlice L. Mitchell
Alice L. Mitchell
ALAnita Lövgren‐Sandblom
Anita Lövgren‐Sandblom
NSNithya Sukumar
Nithya Sukumar
CWCatherine Williamson
Catherine Williamson
Objective: Investigation of serum bile acid profiles in pregnancies complicated by gestational diabetes mellitus (GDM) in a multi‐ethnic cohort of women who are lean or obese.Design: Prospective cohort study.Setting: UK multicentre study.Population: Fasting serum from participants of European or South Asian self‐reported ethnicity from the PRiDE study, between 23 and 31 weeks of gestation.Methods: Bile acids were measured using ultra‐performance liquid chromatography‐tandem mass spectrometry. Log‐transformed data were analysed using linear regression in STATA/IC 15.0.Main outcome measures: Total bile acids (TBAs), C4, fasting glucose and insulin.Results: The TBAs were 1.327‐fold (1.105–1.594) increased with GDM in European women (P = 0.003). Women with GDM had 1.162‐fold (1.002–1.347) increased levels of the BA synthesis marker C4 (P = 0.047). In South Asian women, obesity (but not GDM) increased TBAs 1.522‐fold (1.193–1.942, P = 0.001). Obesity was associated with 1.420‐fold (1.185–1.702) increased primary/secondary BA ratio (P < 0.001) related to 1.355‐fold (1.140–1.611) increased primary BA concentrations (P = 0.001). TBAs were positively correlated with fasting glucose (P = 0.039) in all women, and with insulin (P = 0.001) and the Homeostatic Model Assessment for Insulin Resistance (HOMA‐IR) (P = 0.001) in women with GDM.Conclusions: Serum BA homeostasis in late gestation depends on body mass index and GDM in ethnicity‐specific ways. This suggests ethnicity‐specific aetiologies may contribute to metabolic risk in European and South Asian women, with the relationship between BAs and insulin resistance of greater importance in European women. Further studies into ethnicity‐specific precision medicine for GDM are required.

19 June 2025 in The Journal of Physiology
Verified
Journal Article
Open access
JSJosca Schoonejans
Josca Schoonejans
PWPhoebe Wilsmore
Phoebe Wilsmore
LMLais Vales Mennitti
Lais Vales Mennitti
KWKwun K. Wong
Kwun K. Wong
TAThomas J. Ashmore
Thomas J. Ashmore
Susan OzanneSusan Ozanne
Susan Ozanne
Metformin is increasingly used to treat diabetes in pregnancy, but the effects on adult offspring health remain under‐explored. The present study investigated the long‐term cardiovascular effects in male and female offspring of maternal metformin treatment using a well‐established mouse model of obese glucose intolerant pregnancy. Female mice were given chow, or an obesogenic diet with/without 300 mg kg−1 day−1 oral metformin during gestation. At 3, 6 and 12 months of age, male and female offspring were studied longitudinally with tail‐cuff plethysmography and echocardiography. At 12 months, tissues were collected for wire myography, histology and molecular analyses. Female offspring of obese dams had elevated blood pressure throughout life, cardiac diastolic dysfunction at 3 months, and increased femoral vasoconstrictor reactivity and aortic wall remodelling at 12 months. Metformin treatment did not ameliorate these effects and led to obesity‐induced hypertension at 12 months. Irrespective of metformin, male offspring of obese pregnancy had cardiac diastolic dysfunction from 6 months without changes in blood pressure. Male metformin‐exposed offspring also showed cardiomegaly, increased cardiac collagen and vascular sympathetic hyperreactivity, suggesting metformin exposure worsened the cardiovascular phenotype. These findings show that maternal obesity caused sex‐specific cardiovascular aberrations in aged offspring. Maternal metformin was not corrective and introduced further sex‐dependent cardiovascular alterations. Further long‐term offspring follow up of both sexes is needed for informed decisions about metformin during pregnancy. image Key points: The oral medication metformin is increasingly used to treat diabetes in pregnancy. Metformin readily crosses the placenta, and long‐term effects on offspring cardiovascular health remain unexplored in human and animal studies. In a mouse model of maternal diet‐induced obesity with impaired glucose tolerance, female and male offspring developed hypertension and diastolic cardiac dysfunction, respectively, by 12 months of age (equivalent to middle age in humans). Maternal metformin treatment worsened the cardiovascular phenotype and introduced further sex‐dependent cardiovascular alterations in both male (cardiac stiffening, vascular dysfunction) and female (obesity‐induced hypertension) offspring. This work highlights that long‐term cardiovascular follow up in offspring of both sexes from human pregnancies treated with metformin is crucial to make more informed decisions about metformin use in diabetic pregnancy.